Akamis Bio's clinical-stage NG-350A tumor gene therapy to be included as a novel combination therapeutic agent in a new cohort of the REVOLUTION platform study New cohort will assess the ability of
Cancer-causing gene mutation KRAS, found in nearly 30 per cent of all human tumours, successfully shrunk tumours or stopped cancer growth in preclinical models of pancreatic cancer.
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.
KRAS drug stops cancer growth in preclinical models of pancreatic cancer: Study webindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webindia123.com Daily Mail and Mail on Sunday newspapers.
KRAS drug stops cancer growth in preclinical models of pancreatic cancer: Study pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.